Log In
Print
BCIQ
Print
Print this Print this
 

sovaprevir (formerly ACH-1625)

  Manage Alerts
Collapse Summary General Information
Company Achillion Pharmaceuticals Inc.
DescriptionSelective inhibitor of HCV NS3 protease
Molecular Target HCV NS3 protease
Mechanism of ActionViral protease inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotype 3 infection; Treat chronic HCV genotype 1 infection; Treat chronic HCV infection; Treat HCV genotype 1 infection
Regulatory Designation U.S. - Fast Track (Treat chronic HCV infection)
Partner Johnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,125.0M

0

$900.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today